Can DNA predict who responds to Teverelix? A new UAE endometriosis trial aims to find out

Medicus Pharma Ltd. has received Investigational New Drug authorization from the United Arab Emirates Department of Health in Abu Dhabi to proceed with the PRECISION-E2 Phase 2a study of Teverelix in women with moderate-to-severe symptomatic endometriosis. The randomized, placebo-controlled trial is designed to enroll approximately 84 participants across multiple sites and compare three Teverelix regimens with placebo. Its primary pharmacodynamic endpoint will test whether treatment can keep serum estradiol within an approximately 20 to 50 pg/mL therapeutic range for at least 14 consecutive days. The study will also combine genomic, hormonal, pharmacokinetic, safety and patient-reported data to explore why treatment responses differ among women. The authorization advances Medicus Pharma’s women’s health strategy, although site-specific ethics and Institutional Review Board approvals are still required before dosing can begin.

UAE authorization turns the Teverelix filing into a near-executable clinical program

The July 31 decision is more meaningful than Medicus Pharma’s June announcement that it had submitted the study application. The Department of Health reviewed the company’s chemistry, manufacturing and controls package together with non-clinical, clinical and safety documentation before authorizing the study to proceed. A national regulatory obstacle has therefore been removed, but the announcement does not mean enrollment or patient treatment has started.

Participants will be assigned equally to four groups: 60 milligrams of Teverelix administered subcutaneously, 90 milligrams administered subcutaneously, 90 milligrams administered intramuscularly or subcutaneous placebo. Testing two doses and two administration routes within the same trial could help determine which regimen offers the best combination of hormonal control, exposure and tolerability for later development.

Teverelix is a long-acting injectable gonadotropin-releasing hormone antagonist developed by Medicus Pharma through Antev Ltd. It is designed to suppress reproductive hormones rapidly and reversibly without the initial hormonal flare associated with gonadotropin-releasing hormone agonists. The depot formulation may also support less-frequent dosing than daily oral antagonists, but PRECISION-E2 must show whether that pharmacologic profile produces a practical benefit for women with symptomatic disease.

PRECISION-E2 targets controlled estradiol suppression rather than maximum hormone shutdown

The study is not designed simply to reduce estradiol as far as possible. Its primary endpoint will measure the proportion of participants who maintain estradiol within the established Barbieri therapeutic window of approximately 20 to 50 pg/mL for at least 14 consecutive days. The objective is to suppress an estrogen-driven disease while avoiding unnecessary hypoestrogenic effects that can undermine tolerability.

Secondary and exploratory measures include drug exposure, luteinizing hormone, follicle-stimulating hormone, bone turnover markers, immunogenicity, safety, endometriosis-associated pain and quality of life. These outcomes will indicate whether a dose can produce durable hormonal control without imposing a burden that limits adherence or treatment duration.

Two earlier Phase 1 studies involving 48 healthy premenopausal women provided the pharmacologic basis for moving into patients. Medicus Pharma reported predictable and reversible estradiol suppression, rapid initial absorption, sustained exposure with a secondary concentration peak after one to three weeks and an estimated terminal half-life of approximately 14 to 23 days. The company also reported that bone turnover biomarkers remained within normal ranges through Day 29 and that no unexpected safety signals emerged.

Those findings are encouraging but do not establish efficacy in endometriosis. Healthy-volunteer studies can characterize dose behavior and preliminary safety, yet they cannot demonstrate meaningful reductions in pain or improvements in quality of life. PRECISION-E2 is therefore the first important test of whether Teverelix’s hormonal effects translate into a patient-level signal strong enough to justify a larger clinical program.

Genomic profiling may identify likely responders, but the evidence will remain exploratory

The most distinctive element of PRECISION-E2 is its prospective integration of genomic information with endocrine pharmacology and clinical outcomes. Researchers plan to examine whole-genome information and predefined pathways connected to estrogen signaling, estrogen synthesis, gonadotropin activity, inflammation, pain perception and endometriosis biology. Candidate genes include ESR1, ESR2, CYP19A1, GNRHR, FSHR and LHCGR.

This design may help Medicus Pharma determine whether particular genetic patterns are associated with successful estradiol control, symptom improvement, tolerability or drug exposure. A credible association could influence dose selection, later trial enrollment and potential biomarker-informed development rather than treating all patients as biologically identical.

The limitation is sample size. A study of approximately 84 women is small for discovering dependable multi-gene response signatures, especially when investigators are evaluating numerous genomic and clinical variables. Medicus Pharma has acknowledged that any candidate biomarker or multi-gene signature would need confirmation in later studies before being used to select patients.

Population transferability will also require scrutiny. Signals found in a UAE population may provide valuable biological insight, but they cannot automatically be assumed to perform identically across different ancestral and clinical groups. The most realistic near-term result may be a focused set of hypotheses for validation rather than an immediately deployable precision-medicine test.

Even so, the combined dataset could be more decision-useful than a conventional small Phase 2 trial. Exposure, hormone levels, symptoms, quality of life, safety, bone biology and genomics may help explain not only whether Teverelix works, but why a regimen succeeds or fails. That information could guide Medicus Pharma’s own development choices and improve the program’s appeal to potential pharmaceutical partners.

Medicus Pharma gains a clinical catalyst while financing and listing risks stay visible

Endometriosis affects an estimated 10% of reproductive-age women worldwide, or about 190 million people, according to the World Health Organization. It can cause severe menstrual pain, chronic pelvic pain, heavy bleeding and infertility, while diagnosis and access to treatment are often delayed. A differentiated long-acting therapy could therefore address a substantial market if efficacy, safety and dosing convenience are ultimately demonstrated.

Raza Bokhari, executive chairman and chief executive officer of Medicus Pharma, said the authorization supported a development strategy combining endocrinology, pharmacology and population genomics. He indicated that the study could optimize Teverelix and inform personalized approaches to endometriosis and other estrogen-driven conditions. That ambition now depends on site activation, enrollment execution and whether hormonal control is accompanied by convincing symptom and tolerability data.

Investor sentiment was positive after the announcement. Medicus Pharma shares traded near $0.2795 late Friday afternoon on July 31, approximately 6.4% above the previous close, after reaching an intraday high of about $0.3011. Trading volume was approximately 3.89 million shares, suggesting the authorization attracted meaningful short-term interest.

The reaction must be viewed in the context of a speculative clinical-stage company. Medicus Pharma reported $6.37 million in cash and equivalents at March 31, 2026, while using $8.97 million in operating cash during the first quarter. The company also raised money through an at-the-market program and a standby equity purchase agreement, tools that can extend its runway but may dilute existing shareholders.

Medicus Pharma also disclosed that its shares were below the Nasdaq Capital Market’s $1 minimum bid requirement and that it had until October 19, 2026, under the initial compliance period to regain the required price. The listing issue does not change the scientific value of PRECISION-E2, but it adds market risk around financing and potential capital-structure actions.

My assessment is that the authorization improves the Teverelix investment narrative because it converts a proposed precision-medicine strategy into a regulator-cleared clinical program. The strongest feature is the study’s ability to examine dose, route and possible responder biology together. The main weakness is that an exploratory 84-patient study cannot validate a genomic treatment-selection platform by itself. Medicus Pharma still needs disciplined execution, interpretable clinical data and sufficient capital before the genomic promise can become a durable commercial advantage.

Key takeaways

• The UAE authorization removes a national regulatory hurdle for PRECISION-E2, but site-level ethics and Institutional Review Board approvals remain necessary before the trial can begin.
• Approximately 84 women will be randomized across three Teverelix regimens and placebo, allowing Medicus Pharma to compare dose and administration route in one study.
• The primary endpoint targets sustained estradiol control within an approximately 20 to 50 pg/mL range, reflecting an effort to balance disease suppression with tolerability.
• The genomic component may uncover candidate predictors of response, but any resulting signature will require validation in a larger independent study.
• Earlier Phase 1 data support long-acting exposure and reversible estradiol suppression, while PRECISION-E2 must establish whether those effects improve symptoms.
• The addressable disease burden is substantial, with the World Health Organization estimating that endometriosis affects roughly 190 million reproductive-age women.
• The positive share-price response signals near-term enthusiasm, although the stock remains volatile and below Nasdaq’s minimum bid requirement.
• Cash burn, equity financing and potential dilution remain important risks as Medicus Pharma advances multiple clinical programs.